Harvard Bioscience to Showcase Array of New Products at Society for Neuroscience 2015 Annual Meeting in Chicago on October 18-21

HOLLISTON, Mass., Oct. 16, 2015 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will feature new and existing products from its expanded portfolio of brands at the Society for Neuroscience 2015 Annual Meeting at Chicago's McCormick Place Convention Center on October 18-21. This year, for the first time, the Company's Harvard Apparatus booth will incorporate a host of instruments from Harvard Bioscience's three recently acquired companies—HEKA Elektronik, Multi Channel Systems and Triangle BioSystems International—directly alongside those from its established brands. There will also be two dedicated workstations in the Harvard Apparatus booth for scheduled one-on-one product demonstrations and training sessions.

New products on display in the Harvard Apparatus booth (Booth #1043) will include:

  • Harvard Apparatus' VentElite, a ventilator for rodents now with touchscreen graphical user interface (GUI) and real-time graphical display
  • Panlab's Treadmill, equipment for exercise training and fatigue resistance studies, now with touchscreen GUI
  • Multi Channel Systems' PatchServer, an automated patch clamp now available in a four-channel version
  • HEKA's new Headstage, smaller lighter with an improved connection to the pipette holder
  • Triangle BioSystems International's Combination 128-channel Recording and 16-channel Stimulation Headstage, now 20 percent smaller and lighter
  • Warner Instruments' DP-304A amplifier with increased settings

The KD Scientific booth (Booth #1174) will spotlight affordable liquid handling products for automated delivery of fluids and gas in the laboratory. Featured this year will be:

  • New Allegro Peristaltic pump system and Centrifan small-volume evaporator
  • Legato 180 Picoliter syringe pump for microdialysis experiments
  • Legato 130 Nanoliter Remote Head pump for stereotaxically guided, single-channel microinjection.

The Company's three symposium events will highlight products from HEKA Elektronik, Multi Channel Systems, Triangle BioSystems International and Warner Instruments:

Sunday, October 18 / 6:30 PM – 8:30 PM
Hyatt Regency Chicago Downtown, Columbian Room
151 East Wacker Drive, Chicago, IL 60601
"PatchMaster: An introduction for beginners and converts"
"Patch Clamp: Presentation of the PatchServer"

Monday, October 19 / 6:30 PM – 7:30 PM
McCormick Place, Room S402
"Wireless in vivo Neural Recording and Stimulation"

Monday, October 19 / 6:30 PM – 7:30 PM
McCormick Place, Room S403
"In vitro Microelectrode Array Recording Techniques"

"The Society for Neuroscience meeting offers the ideal venue for showcasing our increasingly robust and diverse line of products for the modern laboratory researcher," said Mr. Duchemin. "With the full consolidation of products from our HEKA Elektronik, Multi Channel Systems and Triangle BioSystems International acquisitions under the Harvard Bioscience umbrella, we are now able to highlight our brand synergies and product workflows in the Electrophysiology, Behavior and Molecular Analysis market segments."

Jeffrey Duchemin, president and CEO will be attending the Conference.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.

The Harvard Bioscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=23828

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, the impact of acquisitions, or potential acquisitions, the outlook for the life sciences industry, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts.

These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results to differ materially from those in the forward-looking statements include sustained uncertainty concerning government spending; economic and political conditions generally and those affecting pharmaceutical and biotechnology industries; economic, political and other risks associated with international revenues and operations; currency exchange rate fluctuations; the seasonal nature of purchasing in Europe; the Company's failure to expand in Asia and other emerging markets; the Company's inability to manage its growth; competition from the Company's competitors; the Company's failure to expand its product offerings, introduce new products or commercialize new technologies; technological changes resulting in the Company's products becoming obsolete; the Company's failure to identify potential acquisition candidates and successfully close such acquisitions with favorable pricing or integrate acquired businesses or technologies; the Company's failure to raise or generate capital necessary to implement its acquisition and expansion strategy; unanticipated costs relating to acquisitions and known and unknown costs arising in connection with the Company's consolidation of business functions and any restructuring initiatives; failure or inadequacy of the Company's information technology structure; impact of difficulties implementing our enterprise resource planning systems; failure of any banking institution in which the Company deposits its funds or the institution's failure to provide services; the Company's substantial debt and its ability to meet the financial covenants contained in its credit facility; the failure of the Company's spin-off of Harvard Apparatus Regenerative Technology, Inc., or HART, to qualify as a transaction that is generally tax-free for U.S. federal income tax purposes; the failure of HART to indemnify the Company for any liabilities associated with HART's business; impact of any impairment of the Company's goodwill or intangible assets; the Company's ability to retain key personnel; rising commodity and precious metals costs; the Company's ability to protect its intellectual property and operate without infringing on others' intellectual property; exposure to product and other liability claims; plus factors described under the heading "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014, or otherwise described in our other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.

CONTACT: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO 508-893-8999 Dian Griesel Int'l. Investor Relations: Cheryl Schneider Public Relations: Susan Forman or Laura Radocaj 212-825-3210

Source:Harvard Bioscience, Inc.